TROMS0, Norway--(BUSINESS WIRE)--The Scandinavian-based drug development company Lytix Biopharma revealed more information on its lead anti-cancer molecule Oncopore at BIO 2008 in San Diego. The first of a novel class of drugs, Oncopore is based on an anti-cancer pharmacophore of lactoferrin and is the result of systematic QSAR work and extensive preclinical studies.
